Across TCGA pan-cancer cohorts, CYCS Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYCS data layer compared with 23 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CYCS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYCS expression acts as an unfavorable survival marker.
CESC and LUSC are the cancer types where CYCS Mutation most reproducibly stratifies survival.